Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.2869
+0.0005 (0.17%)
At close: May 30, 2025, 4:00 PM
0.3900
+0.1031 (35.94%)
After-hours: May 30, 2025, 7:59 PM EDT
Plus Therapeutics Revenue
In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth. Plus Therapeutics had revenue of $1.41M in the quarter ending December 31, 2024, with 7.54% growth.
Revenue (ttm)
$5.82M
Revenue Growth
+18.54%
P/S Ratio
0.33
Revenue / Employee
$277,333
Employees
21
Market Cap
4.88M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PSTV News
- 9 hours ago - Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 days ago - Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - GlobeNewsWire
- 16 days ago - Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - GlobeNewsWire
- 22 days ago - Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases - GlobeNewsWire
- 2 months ago - Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire